Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial

Data Show Anti-inflammatory ABX464 inhibits SARS-CoV-2 Viral Replication In Lung

 
• By Sten Stovall
  
Covid19_Lungs_Vial
Abivax says ABX464 has ‘unique’ triple action to treat COVID-19 patients • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip